Arquer Diagnostics and the University of Sunderland collaborate to extend application of cancer diagnostic
17th October 2016
13th July 2016
Arquer will be exhibiting at the BAUS 2016 Annual Scientific Meeting BT Convention Centre, Kings Dock, Waterfront Liverpool, Merseyside L3 4FP on 27 – 30 Jun 2016
5th April 2016
8th February 2016
Arquer Diagnostics Receives Ethical Approval for Largest Privately Funded Bladder Cancer Study in UK
11th January 2016
7th December 2015
Welcome to Arquer – developing novel urine diagnostic tests for prostate and bladder cancer
Arquer Diagnostics (Arquer) is a private, UK based diagnostics company focused on the development and commercialisation of a non-invasive immunoassay diagnostic test for bladder and prostate cancer.
Arquer’s diagnostic test, the Mcm5-ELISA, detects the presence of minichromosome maintenance (MCM) protein, a marker for the presence of dividing cancer cells, in urine. MCM proteins are excellent biomarkers, being directly involved in cell replication, and are shed into urine by both prostate and bladder tumours. Arquer’s test is based on intellectual property licensed exclusively from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK.